Logo

JAGX

Jaguar Health, Inc.

JAGX

Jaguar Health, Inc. • NASDAQ
$1.35 ▲ 5.47% (+0.07)
Market Cap $2.94 M
52w High $33.25
52w Low $1.10
Dividend Yield 0%
P/E -0.52
Volume 42.83K
Outstanding Shares 2.17M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.083M ▲ $9.229M ▼ $-9.502M ▲ -308.206% ▲ $-6.28 ▲ $-9.082M ▼
Q2-2025 $2.979M ▲ $10.459M ▼ $-10.407M ▲ -349.345% ▲ $-10.26 ▲ $-7.451M ▲
Q1-2025 $2.214M ▼ $11.12M ▲ $-10.464M ▼ -472.629% ▼ $-16.7 ▲ $-8.875M ▲
Q4-2024 $3.509M ▲ $11.109M ▲ $-9.92M ▼ -282.702% ▲ $-33.68 ▼ $-15.753M ▼
Q3-2024 $3.108M $9.829M $-9.854M -317.053% $-26.25 $-6.666M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.527M ▲ $49.472M ▲ $45.113M ▲ $5.627M ▼
Q2-2025 $2.207M ▼ $48.268M ▼ $41.388M ▼ $7.988M ▲
Q1-2025 $5.69M ▼ $51.46M ▼ $50.63M ▲ $1.782M ▼
Q4-2024 $8.002M ▼ $53.425M ▼ $46.931M ▲ $7.285M ▼
Q3-2024 $13.269M $58.466M $45.368M $13.612M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-9.502M ▲ $-4.689M ▲ $-54K ▼ $6.259M ▲ $1.32M ▲ $-4.743M ▲
Q2-2025 $-10.583M ▼ $-6.193M ▲ $0 $2.655M ▼ $-3.481M ▼ $-6.193M ▲
Q1-2025 $-10.464M ▼ $-7.316M ▲ $0 ▲ $4.966M ▲ $-2.314M ▲ $-7.316M ▲
Q4-2024 $-9.92M ▲ $-7.826M ▼ $-215K ▼ $2.83M ▼ $-5.267M ▼ $-7.826M ▼
Q3-2024 $-10.339M $-6.341M $0 $3.53M $-2.78M $-6.325M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
License
License
 $0 ▲$0 ▲$0 ▲$0 ▲
Mytesi
Mytesi
 $10.00M ▲$0 ▼$0 ▲$0 ▲
Neonorm
Neonorm
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Jaguar Health has remained a very small, loss‑making business over the past several years. Revenue has been minimal and fairly flat, suggesting that its approved products have not yet scaled commercially. Operating losses have been steady and sizable relative to sales, reflecting a cost base (R&D, selling, and overhead) that is far larger than the revenue stream. Net losses have persisted each year, and per‑share results look extremely volatile and heavily negative, largely because of repeated reverse stock splits and equity-related changes rather than sudden swings in the underlying operations.

Balance Sheet

Balance Sheet The balance sheet looks thin and stretched. Total assets are modest, with only a small cash cushion, while debt makes up a large share of the capital structure. Shareholders’ equity has hovered close to break‑even at times, which is a sign of accumulated losses and limited balance‑sheet strength. Overall, the company appears financially fragile and heavily reliant on outside capital to fund its activities, leaving little margin for error if operations or financing access were to weaken.

Cash Flow

Cash Flow Cash flow from the core business has been consistently negative, meaning the company is burning cash each year to support operations. Capital spending needs are low, so the cash drain is coming mainly from ongoing R&D, commercial efforts, and overhead rather than big investments in physical assets. This pattern suggests Jaguar Health must regularly seek new funding—through debt, equity, or partnerships—to keep running its programs and maintain its product portfolio.

Competitive Edge

Competitive Edge Competitively, Jaguar occupies a narrow but differentiated niche: plant‑derived, non‑opioid treatments for gastrointestinal problems in humans and animals. Its lead product, Mytesi, is unique but currently serves a small, specialized HIV‑related indication, which limits revenue scale and brand visibility. The company faces indirect competition from broader GI and supportive‑care treatments sold by much larger pharmaceutical firms with far greater marketing and financial firepower. However, Jaguar’s extensive patent portfolio, botanical drug know‑how, and vertically integrated supply chain for its key ingredient create meaningful barriers for would‑be imitators, giving it a technical moat even if its commercial footprint is still small.

Innovation and R&D

Innovation and R&D Innovation is the core of Jaguar’s story. The company is building a platform around crofelemer, a first‑in‑class, plant‑based therapy with a distinct mechanism that normalizes fluid balance in the gut without opioid side effects. It is extending this platform into multiple areas: rare pediatric intestinal diseases, short bowel syndrome, cancer‑related diarrhea, and potentially gastrointestinal side effects linked to popular weight‑loss and diabetes drugs. It is also developing animal‑health applications and exploring plant‑based medicines for mental health via a joint venture. These efforts, backed by a large patent estate and orphan‑drug strategies, represent meaningful upside potential but come with high clinical, regulatory, and execution risk and require ongoing investment to reach approval and commercial relevance.

Summary

Jaguar Health combines a financially stressed profile with a scientifically interesting, highly specialized pipeline. On the financial side, it is a small company with limited revenue, recurring losses, and a fragile balance sheet that depends on external funding—something underscored by a long history of large reverse stock splits. On the strategic side, it has carved out a differentiated position in plant‑derived gastrointestinal therapies supported by strong intellectual property, unique regulatory status for its lead drug, and a sustainable supply chain. The long‑term outcome hinges on whether the company can successfully translate its R&D into approvals for broader or higher‑value indications and then execute commercially at scale, all while managing its cash burn and access to capital in a disciplined way.

NEWS

November 24, 2025 · 9:00 AM UTC

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

Read more

November 20, 2025 · 9:00 AM UTC

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

Read more

November 17, 2025 · 8:00 AM UTC

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

Read more

November 14, 2025 · 9:00 AM UTC

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

Read more

November 13, 2025 · 9:00 AM UTC

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

Read more